REVELATION BIOSCIENCES, INC. (REVB)
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Revelation Biosciences, Inc.
REVELATION BIOSCIENCES, INC. (REVB) dilution facts from SEC filings
Snapshot as of Sep 30, 2026, built from 33 SEC filings.
- At-the-market (ATM) program
- No active program in the filings reviewed
- Warrants outstanding
- 13 warrant series recorded as outstanding
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.